Modality
Multispecific
MOA
TYK2i
Target
PSMA
Pathway
Amyloid
HNSCCRettMM
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
~Jun 2020
→ ~Sep 2021
Phase 3
Dec 2021
→ Nov 2030
Phase 3Current
NCT05293796
829 pts·HNSCC
2022-07→2029-07·Completed
NCT06591690
1,264 pts·MM
2021-12→2030-11·Not yet recruiting
2,093 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-07-083.3y awayPh3 Readout· HNSCC
2030-11-104.6y awayPh3 Readout· MM
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Not yet…
P3
Complet…
Catalysts
Ph3 Readout
2029-07-08 · 3.3y away
HNSCC
Ph3 Readout
2030-11-10 · 4.6y away
MM
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05293796 | Phase 3 | HNSCC | Completed | 829 | LiverFat |
| NCT06591690 | Phase 3 | MM | Not yet recr... | 1264 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Doxacagene | Sanofi | Approved | PSMA | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 |